Page last updated: 2024-09-04

pomalidomide and Idiopathic Parkinson Disease

pomalidomide has been researched along with Idiopathic Parkinson Disease in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Bernardini, R; Burgaletto, C; Cantarella, G; Carboni, E; Cardia, MC; Carta, AR; Casu, MA; Coroneo, V; De Simone, A; Ena, A; Etzi, M; Fusco, G; Greig, NH; Lai, F; Palmas, MF; Picci, L; Pisanu, A; Scerba, MT; Tweedie, D1

Other Studies

1 other study(ies) available for pomalidomide and Idiopathic Parkinson Disease

ArticleYear
Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease.
    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2022, Volume: 19, Issue:1

    Topics: alpha-Synuclein; Animals; Cytokines; Disease Models, Animal; Disease Progression; Drug Repositioning; Humans; Microglia; Neuroprotective Agents; Parkinson Disease; Rats; Substantia Nigra; Thalidomide; Tumor Necrosis Factor-alpha

2022